D121 is a NCE that has a very good potential to treat multiple infectious diseases that lead to global health threats.

Within a One Health approach the further development of D121 has a strong potential to give an answer to multiple zoonotic infectious diseases.

For companion animals (dogs) D121 is at TRL 7 heading for TRL 8, market authorization.

Oblita has assured a lot of private and non-dilutive funding. An additional investment round will support bringing the canine leishmaniasis product to market within four years.

In the pipeline for animal health:

• Cryptosporidiosis for neonatal calves
• Derman fungal diseases in companion animals / horses / livestock

For human drug development, we are at the end of phase I.

• An outstanding network of leishmaniasis clinicians is standing ready for an IND submission at FDA as for conducting phase II and III clinical trials in Old and New World. Upon approval of NDA, this NCE is eligible for a Priority Review Voucher
• Qualified Infectious Disease Program is in the pipeline for Invasive Fungal Disease

Interested in receiving an investment proposal? Please fill in the form.